Bristol Myers Squibb CO Form 4 insider transactions

Phyllis R Yale, a Director of Bristol Myers Squibb Co, received 561 shares of common stock on September 30, 2026.

Theodore R. Samuels Ii, a Director of Bristol Myers Squibb Co, received 821 shares of common stock on September 30, 2026.

Derica W Rice, a Director of Bristol Myers Squibb Co, received 621 shares of common stock on September 30, 2026.

Michael R. Mcmullen, a Director of Bristol Myers Squibb Co, received 561 shares of common stock on September 30, 2026.

Peter J Arduini, a Director of Bristol Myers Squibb Co, received 561 shares of common stock on September 30, 2026.

Cristian Massacesi, EVP,Chief Med Offr,Head of Dev of Bristol Myers Squibb Co, sold 6,249 shares of common stock on September 9, 2026 for $64.57 per share.

Phil M Holzer, SVP and Controller of Bristol Myers Squibb Co, sold 500 shares of common stock on August 25, 2026 for $67.50 per share.

Cristian Massacesi, EVP,Chief Med Offr,Head of Dev of Bristol Myers Squibb Co, reported multiple transactions in common stock on August 1, 2026.

Phyllis R. Yale, a Director at Bristol Myers Squibb, reported a transaction involving deferred share units.

Theodore R. Samuels II, a Director at Bristol Myers Squibb, reported transactions involving deferred share units.

Bristol Myers Squibb Director Derica W. Rice reported transactions involving deferred share units.

Julia A. Haller, a Director at Bristol Myers Squibb, reported a transaction involving the exercise of stock options and acquisition of common stock.

EVP Wendy Short Bartie acquired 8,040 shares of Bristol Myers Squibb common stock via restricted stock unit vesting.

EVP and Chief Commercial Officer Adam Lenkowsky reported the vesting and tax-related disposition of Bristol Myers Squibb market share units.

EVP Karin Shanahan reported the vesting of restricted stock units and subsequent tax-related share withholding for Bristol Myers Squibb.

Bristol-Myers Squibb CFO David V. Elkins sold 30,000 shares of common stock pursuant to a pre-established Rule 10b5-1 trading plan.

Director Phyllis R. Yale acquired 577.082 deferred share units in Bristol-Myers Squibb as part of director compensation.

Bristol-Myers Squibb director Theodore R. Samuels II acquired 845.012 deferred share units as part of director compensation.

Bristol-Myers Squibb director Derica W. Rice acquired 638.912 deferred share units as part of director compensation.

Bristol Myers Squibb director Michael R. McMullen acquired 577.082 deferred share units as part of director compensation.

Bristol-Myers Squibb director Peter J. Arduini acquired 577.082 deferred share units as part of director compensation.

Bristol-Myers Squibb's President of RayzeBio Org. received significant performance-based equity awards.

Bristol-Myers Squibb's EVP, Chief Strategy Officer, Hiroshi Chris Shibutani, was granted 19,592 performance-based equity units.

Bristol-Myers Squibb's EVP, Chief Medical Officer, Cristian Massacesi, received grants of 26,122 Market Share Units and 39,184 Performance Shares.

Bristol-Myers Squibb EVP Wendy Short Bartie reported significant equity transactions, including vesting of market share units and performance shares, and new grants.

Bristol-Myers Squibb EVP Robert M. Plenge reported significant equity transactions, including vesting of performance awards and new grants, alongside tax-related share dispositions.

Bristol-Myers Squibb EVP Gregory Scott Meyers reported significant equity transactions, including vesting of market share units and performance shares, along with new grants.

Bristol-Myers Squibb's EVP, Chief Commercial Officer Adam Lenkowsky, reported the vesting of equity awards, tax-related dispositions, and new grants of market share units and performance shares.

Bristol-Myers Squibb's SVP and Controller, Phil M. Holzer, reported routine acquisitions and dispositions of company common stock and derivative securities related to compensation plans.

Bristol-Myers Squibb CEO Christopher S. Boerner reported the vesting of various equity awards, associated tax withholdings, performance-based adjustments, and new grants of market share units and performance shares.